← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Closed-loop transcranial focused ultrasound with 40Hz gamma (PVALB) — 1.00 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen (TREM2) — 0.99 SASP Modulation Rather Than Cell Elimination (NFKB1,IL1B,BDNF) — 0.98 TREM2-Dependent Microglial Senescence Transition (TREM2) — 0.95 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.95 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.94 PLCG2 Allosteric Modulation as a Precision Therapeutic for T (PLCG2) — 0.94 Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 (CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes) — 0.94 Multi-Biomarker Composite Index Surpassing Amyloid PET for T (COMPOSITE_BIOMARKER) — 0.93 Closed-loop focused ultrasound targeting CA1 PV interneurons (PVALB) — 0.93 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.92 CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli (CYP46A1) — 0.92 Autophagy-Senescence Axis Therapeutic Window (ATG7,BCL2,BCL2L1) — 0.92 Selective Acid Sphingomyelinase Modulation Therapy (SMPD1) — 0.92 HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM (HK2) — 0.92 Palmitoylethanolamide-Based Endocannabinoid Therapy (PPARA) — 0.92 CYP46A1 Overexpression Gene Therapy (CYP46A1) — 0.92 Chromatin Remodeling-Mediated Nutrient Sensing Restoration (SMARCA4) — 0.91 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 SASP-Mediated Complement Cascade Amplification (C1Q/C3) — 0.91 TREM2-ASM Crosstalk in Microglial Lysosomal Senescence (SMPD1) — 0.91 TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene (TREM2) — 0.91 Nutrient-Sensing Epigenetic Circuit Reactivation (SIRT1) — 0.91 Closed-loop focused ultrasound targeting EC-II SST interneur (SST) — 0.90 CSF1R Inhibition-Mediated Microglial Replacement as a State (CSF1R) — 0.90 Closed-loop tACS targeting EC-II SST interneurons to block t (SST) — 0.90 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.90 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.89
Add
|
× Metabolic Reprogramming t
SIRT1,PGC1A,NAMPT · - · therapeutic
Composite 1.000
Price $0.98
Evidence For 0
Evidence Against 0
# Metabolic Reprogramming to Reverse Senescence in Neurodegeneration: A Mechanistic Hypothesis
## The Senescence Conundrum in Neurodegenerative Disease
Cellular senescence, traditionally characterized as an irreversible cell cycle arrest, has emerged as a critical pathophysiological feature across neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. While senolytic approaches have gained traction as therapeutic strategies—focused o
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Metabolic Reprogramming to Rev Mechanistic 0.800 Evidence 0.790 Novelty 0.600 Feasibility 0.900 Impact 0.820 Druggability 0.900 Safety 0.900 Competition 0.700 Data 0.800 Reproducible 0.800
Evidence Metabolic Reprogramming to Reverse Senescence No evidence citations yet
Price History Overlay
Knowledge Graph Comparison
Metabolic Reprogramming to Reverse Senes
71 edges
Top Node Types gene 60
disease 6
drug 3
pathway 2
Top Relations co_discussed 57
investigated_in 7
activates 3
associated_with 2
contributes_to 1